mitoxantrone hydrochloride liposome + capecitabine

Mitoxantrone hydrochloride liposome + capecitabine is a **combination regimen** of two anticancer agents under clinical investigation primarily for **recurrent metastatic nasopharyngeal carcinoma** in patients who have failed platinum-based therapy[1][3][5][7]. - **Mitoxantrone hydrochloride liposome** is a liposomal formulation of mitoxantrone, an anthracenedione DNA intercalator and topoisomerase II inhibitor, designed to enhance tumor targeting and minimize systemic toxicity. Liposomal encapsulation extends circulation time and may reduce cardiotoxicity relative to conventional mitoxantrone[4][5]. - **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU), which exerts cytotoxic effects by inhibiting thymidylate synthase and disrupting DNA synthesis. The combination aims to enhance antitumor efficacy through **synergistic inhibition of DNA replication and repair** pathways, leveraging distinct but complementary mechanisms of action.

Brand names

DuoendaXeloda

Other names

mitoxantrone hydrochloride liposome and capecitabinemitoxantrone hydrochloride liposome injection plus capecitabine